BNP Paribas Asset Management
APGE icon

BNP Paribas Asset Management’s Apogee Therapeutics APGE Stock Holding History

BNP Paribas Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.58M Buy
54,437
+14,591
+37% +$1.06M 0.01% 881
2025
Q4 		$3.01M Buy
39,846
+39,644
+19,626% +$2.5M ﹤0.01% 970
2025
Q3 		$8K Hold
202
– – ﹤0.01% 1682
2025
Q2 		$9K Buy
+202
New +$7.68K ﹤0.01% 1797

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BNP Paribas Asset Management's APGE Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Apogee Therapeutics (APGE) stake by 37% in Q1 2026, buying an estimated $1.06M and bringing the position to 54,437 shares worth $4.58M. The position accounts for 0.01% of the portfolio, ranked #881.

BNP Paribas Asset Management first reported a position in APGE in Q2 2025 and has held it in 4 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • BNP Paribas Asset Management held 54,437 shares of Apogee Therapeutics worth $4.58M as of Q1 2026.
  • BNP Paribas Asset Management bought 14,591 Apogee Therapeutics shares in Q1 2026, an estimated $1.06M.
  • Apogee Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #881 holding.
  • BNP Paribas Asset Management first reported a position in Apogee Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.